NASDAQ:INVAInnoviva Stock Price, Forecast & News

Innoviva's stock was trading at $12.04 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, INVA shares have increased by 11.0% and is now trading at $13.37. View which stocks have been most impacted by Coronavirus.

Innoviva is scheduled to release its next quarterly earnings announcement on Wednesday, July 22nd 2020. View our earnings forecast for Innoviva.

Innoviva Inc (NASDAQ:INVA) announced its quarterly earnings results on Wednesday, April, 29th. The biotechnology company reported $0.59 EPS for the quarter, topping analysts' consensus estimates of $0.36 by $0.23. The biotechnology company earned $78.68 million during the quarter. Innoviva had a return on equity of 59.11% and a net margin of 66.50%. View Innoviva's earnings history.

News articles about INVA stock have been trending positive on Friday, InfoTrie Sentiment Analysis reports. The research firm scores the sentiment of media coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. Innoviva earned a news impact score of 3.0 on InfoTrie's scale. They also gave news coverage about the biotechnology company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the stock's share price in the near term. View the latest news about Innoviva.

Innoviva saw a increase in short interest during the month of June. As of June 15th, there was short interest totaling 12,650,000 shares, an increase of 7.0% from the May 31st total of 11,820,000 shares. Based on an average daily trading volume, of 830,900 shares, the days-to-cover ratio is presently 15.2 days. Approximately 18.4% of the company's shares are short sold. View Innoviva's Current Options Chain.

Some companies that are related to Innoviva include Amgen (AMGN), Gilead Sciences (GILD), Celgene (CELG), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), Biogen (BIIB), Seattle Genetics (SGEN), Alexion Pharmaceuticals (ALXN), Incyte (INCY), BioMarin Pharmaceutical (BMRN), Alnylam Pharmaceuticals (ALNY), EXACT Sciences (EXAS), Neurocrine Biosciences (NBIX), Immunomedics (IMMU) and Ionis Pharmaceuticals (IONS). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Innoviva investors own include Inovio Pharmaceuticals (INO), Exelixis (EXEL), Gilead Sciences (GILD), Sangamo Therapeutics (SGMO), Micron Technology (MU), Pfizer (PFE), ImmunoGen (IMGN), Nektar Therapeutics (NKTR), Occidental Petroleum (OXY) and Progenics Pharmaceuticals (PGNX).

Innoviva trades on the NASDAQ under the ticker symbol "INVA."

Innoviva's stock is owned by many different retail and institutional investors. Top institutional shareholders include Envestnet Asset Management Inc. (0.04%) and 6 Meridian (0.01%). Company insiders that own Innoviva stock include Geoffrey Hulme, George Bickerstaff, Innoviva, Inc, Marianne Zhen and Theodore J Jr Witek. View institutional ownership trends for Innoviva.

INVA stock was sold by a variety of institutional investors in the last quarter, including 6 Meridian. View insider buying and selling activity for Innoviva.

INVA stock was purchased by a variety of institutional investors in the last quarter, including Envestnet Asset Management Inc.. Company insiders that have bought Innoviva stock in the last two years include Geoffrey Hulme, George Bickerstaff, and Innoviva, Inc. View insider buying and selling activity for Innoviva.

Shares of INVA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of INVA stock can currently be purchased for approximately $13.37.

Innoviva has a market capitalization of $1.35 billion and generates $261.02 million in revenue each year. The biotechnology company earns $157.29 million in net income (profit) each year or $1.43 on an earnings per share basis. Innoviva employs 6 workers across the globe.

The official website for Innoviva is www.inva.com.

Innoviva's mailing address is 1350 OLD BAYSHORE HIGHWAY SUITE 400, BURLINGAME CA, 94010. The biotechnology company can be reached via phone at 650-238-9600 or via email at [email protected]